Abstract: We aimed to review the current state-of-the-art imaging methods used for primary and secondary staging of prostate cancer, mainly focusing on multiparametric magnetic resonance imaging and positron-emission tomography/computed tomography with new radiotracers. An expert panel of urologists, radiologists and nuclear medicine physicians with wide experience in prostate cancer led a PubMed/MEDLINE search for prospective, retrospective original research, systematic review, meta-analyses and clinical guidelines for local and systemic staging of the primary tumor and recurrence disease after treatment. Despite magnetic resonance imaging having low sensitivity for microscopic extracapsular extension, it is now a mainstay of prostate cancer diagnosis and local staging, and is becoming a crucial tool in treatment planning. Cross-sectional imaging for nodal staging, such as computed tomography and magnetic resonance imaging, is clinically useless even in high-risk patients, but is still suggested by current clinical guidelines. Positron-emission tomography/computed tomography with newer tracers has some advantage over conventional images, but is not cost-effective. Bone scan and computed tomography are often useless in early biochemical relapse, when salvage treatments are potentially curative. New imaging modalities, such as prostatespecific membrane antigen positron-emission tomography/computed tomography and whole-body magnetic resonance imaging, are showing promising results for early local and systemic detection. Newer imaging techniques, such as multiparametric magnetic resonance imaging, whole-body magnetic resonance imaging and positron-emission tomography/computed tomography with prostate-specific membrane antigen, have the potential to fill the historical limitations of conventional imaging methods in some clinical situations of primary and secondary staging of prostate cancer.
Abbreviations & Acronyms 18F-FACBC = anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid 18F-FDG = 18F-fluorodeoxyglucose ACR = American College of Radiology ADC = apparent diffusion coefficient AUA = American Urological Association BR = biochemical relapse BS = bone scan CAPRA = Cancer of the Prostate Risk Assessment CT = computed tomography DCE = dynamic contrast-enhanced DCEI = dynamic contrast-enhanced imaging DR = detection rate DWI = diffusion-weighted imaging EAU = European Association of Urology ECE = extracapsular extension Ga = gallium 68 LN = lymph node mpMRI = multiparametric magnetic resonance imaging MRI = magnetic resonance imaging NCCN = National Comprehensive Cancer Network NICE = National Institute for Health and Care Excellence NPV = negative predictive value PCa = prostate cancer PET = positron-emission tomography PI-RADS = Prostate Imaging Reporting and Data System PPV = positive predictive value PSA = prostate-specific antigen PSMA = prostate-specific membrane antigen RP = radical prostatectomy RT = radiation therapy SI = signal intensity T2WI = T2-weighted imaging TRUS = transrectal ultrasound wbMRI = whole-body magnetic resonance imaging
Introduction
PCa is the second most common cancer among men and represents the fifth leading cause of cancer death in men worldwide. 1 Historically, local treatments were limited to localized PCa. 2 However, in the past two decades, the potential oncological benefit of primary treatment has been shown even in locally advanced and node-positive disease. 2 Furthermore, recent population-based studies have confirmed that selected oligometastatic patients who underwent RP or RT had improved oncological outcomes compared with those that did not receive local treatment. 3, 4 Therefore, a precise assessment of tumor stage is essential for the correct disease management. At the same time, imaging techniques have progressively improved. TRUS is not accurate for local staging, 5 and multiparametric MRI is emerging as a mainstay for PCa detection and staging, and it is essential for decision-making and the selection of patients suitable for nerve-sparing procedures before RP. 5, 6 PET-CT, usually carried out with choline, is a whole-body molecular imaging modality that has been widely investigated in PCa for primary and secondary staging. 7 New radiotracers, such as 18F-FACBC and 68 Ga-PSMA, have recently been investigated and showed higher accuracy in primary staging and restaging compared with choline and conventional imaging techniques (CT and BS). 8, 9 Despite these advances in PCa imaging, there is poor consensus among the main urological associations in the suggestion of which diagnostic tests should be carried out across the different stages of disease work-up. Furthermore, because of the lack of well-conducted trials in the literature supporting these new imaging techniques, and due to its low availability, the urological associations still recommend the use of conventional imaging techniques in many clinical situations, which can return inaccurate results.
Herein, we report the state-of-the-art PCa imaging in primary and secondary staging, with particular attention to MRI and PET/CT with new radiotracers.
Evidence acquisition
A PubMed/MEDLINE search was carried out up to October 2017 for each study cited in the present article accounting for local and systemic staging of the primary tumor, and local and systemic staging for PCa recurrence after primary treatment. We mainly focused on MRI and PET/CT with a new radiotracer. The search was limited to studies published in English between 1996 and 2017, including prospective, retrospective original research, systematic review, meta-analyses and clinical guidelines. Articles with prominent statistically significant findings were preferred with the consensus of all the authors.
Primary staging in PCa
In the PSA era, localized PCa represents 80-90% of all new diagnoses. 10 Local staging is essentially addressed to the assessment of the ECE and seminal vesicle invasion, and might have some implication on the surgical or radiotherapeutic approach in patients suitable for local treatment. For systemic evaluation, the risk assessment is based on nomograms or stratification in class of risk, and might be critical for treatment planning. In the presence of a high risk of nodal involvement (for example, in the presence of Briganti's nomogram >5% 5 or in intermediate-or high-risk patients according to D'Amico's class of risk), a pelvic LN dissection or pelvic irradiation might be required. Similarly, in the presence of bone or visceral metastasis in newly diagnosed PCa, a systemic approach should be preferred instead of local treatment. The radiological assessment for local or systemic staging is tailored according to the clinical risk (Table 1) .
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Local staging with TRUS and mpMRI TRUS has been widely used for the diagnosis and staging of PCa, showing poor sensitivity in identifying neoplastic lesions, often indistinguishable from normal tissue. TRUS has a limited capability to predict ECE, with a wide range of sensitivity (37 -83%).
12 Color/power Doppler and contrast-enhanced TRUS have shown a moderate improvement in tumor detection, without a significant increase in the staging accuracy. 13, 14 MRI has been applied to the prostate since the early 1980s, with T1-/T2-weighted sequences. Since then, several studies have examined its accuracy in the diagnosis and staging of PCa, with considerable differences in terms of magnetic field strengths, endorectal coil and protocol study related to a variable combination of functional techniques, such as spectroscopy (magnetic resonance spectroscopy), DWI and DCE. 5, 15 In 2012, the European Society of Urogenital Radiology published the first edition of the "prostate MR guidelines" in order to define the appropriate standards for carrying out and reporting the mpMRI, which combines high-resolution T2 and at least two functional techniques, mainly DWI and DCE. It requires a high-field scanner (≥1.5 T) and a combination of pelvic phased-array and endorectal coil; the latter is not an absolute requirement with 3 T. 15, 16 Furthermore, with the aim of easy reporting of the data between radiologists and urologists, they developed a score (PI-RADS score) that assesses the likelihood of cancer, and its eventual degree of ECE, on a 5-point score on each MRI sequence (T2WI, DW-MRI, DCE-MRI), with a precise description of the location of the tumor. 16 This system was validated in several studies, although it had some limitations. 16 Therefore, a revised version was proposed in 2015 (PI-RADS v2), which takes into consideration the location and the size of the lesion, focusing on the "dominant" parameter according to the peripheral or the transitional zone and offering a decision process to assess a final 5-point score, both for the likelihood of clinical cancer and its eventual ECE. 16 In particular, assessing the PI-RADS v2 score, the DWI score is dominant for peripheral zone cancer, and the T2WI score is dominant for transition zone cancer.
To date, PI-RADS v2 is used worldwide for the diagnosis and staging of PCa, showing higher DR and lower interobserver variance in ECE assessment compared with PI-RADS v1. 17 At this moment, the PI-RADS v2 score is widely used with an important impact on clinical practice. Table 2 summarizes the PI-RADS v2 score assignment and the risk categories.
Regarding the studies of MRI published in the literature, there is still a wide variability of results according to the different study population and different end-points (macroscopic or microscopic ECE). In their meta-analysis including seven studies using 1. 19 The authors also stated that sensitivity of T2- 20 Lebacle et al. showed similar results highlighting the remarkable capability of the MRI to provide an anatomical view of the tumor localization (Fig. 1) . 21 In light of this evidence, we recently showed that MRI helps surgeons to improve the oncological safety of a nerve-sparing approach during RP, and is an essential tool for planning the surgical management, thus improving the preservation of the neurovascular bundles and reducing the rate of positive surgical margins. 22 In a series of 137 patients undergoing nerve-sparing RP, the revision of preoperative MRI changes the surgical plan in almost 50% of patients. Furthermore, patients staged with MRI showed significantly lower overall positive surgical margins compared with the control group with no mpMRI (12.4% vs 24.1%; P ≤ 0.01).
Systemic assessment of PCa with crosssectional conventional imaging (CT and MRI)
The clinical staging of PCa is devised using the American Joint Committee on Cancer tumor-node-metastasis system. 23 PCa metastasis can be nodal or osseous in the early phase of tumor spread (Fig. 2) , whereas visceral metastases are particularly rare.
The incidence of metastatic disease is extremely rare in low-risk disease (stage T1-T2, serum PSA <10 ng/mL and Gleason score <7), therefore, metastatic imaging work-up can be safely spared for these patients. 24 For patients with intermediate-(PSA 10-20 ng/mL or Gleason score 7 or cT2b) or high-risk disease (PSA >20 ng/mL or Gleason score >7 or cT2c), 5 the risk of nodal or bone involvement can range between 3% to 10% and 20% to 40%, respectively, 5, 25 and a systemic assessment is required before treatment.
Nodal assessment, at cross-sectional imaging, is based on size and morphological criteria. LNs are classified as suspected if the short-axis diameter is >10 mm (in case of elongated shape) or >8 mm (in case of round shape; Fig. 3 ). 26, 27 Other criteria frequently used are the loss of nodal hilum fat, and the clustering and enhancement characteristics. However, even using all these findings, conventional imaging techniques are not accurate enough to distinguish hyperplastic benign nodes from malignant nodes or to identify nodal micrometastases. A meta-analysis of Hovels et al. found the sensitivity for CT scans of 42% and specificity of 82%. 28, 29 The poor performance of CT for the detection of nodal metastases has been confirmed in other recent studies. MRI of the abdomen and pelvis has the same limited performance of CT for the evaluation of nodal involvement, but this technique is more time-consuming and more expensive than CT, while providing equivalent information regarding nodal metastases. 32 MRI with superparamagnetic contrast agent ("ultra-small" superparamagnetic particle iron oxides) for preferential LN uptake identifies metastatic nodes in which these agents do not accumulate and do not lose SI. After the first encouraging results in studies of PCa and bladder cancer, in which this procedure showed promising accuracy for detection of pelvic metastasis >2 mm in normal-sized LNs, doubts emerged regarding the consistency of these results, and MRI with "ultra-small" superparamagnetic particle iron oxides is no longer available for clinical use. 33, 34 BS has been the most widely used method for evaluating bone metastases of PCa, with a reported wide range of sensitivity and specificity depending on the clinical parameters. 35 The BS DR is widely influenced by PSA level, biopsy Gleason score and clinical stage. 36 In a systematic review examining the role of BS in PCa staging, metastases were detected in 2% of patients with PSA <10 ng/mL, and 6% and 5% of patients with organ-confined cancer and biopsy Gleason score <7, respectively. 37 Even in patients with high-risk disease, the sensitivity of BS remains extremely low (approximately 10%) and its clinical value remains questionable. 38 CT permits a more accurate assessment of bone involvement than conventional plain X-rays, but is less sensitive than BS. CT can be useful in equivocal cases by distinguishing increased uptake on the BS due to metastasis from other causes, such as degenerative disease or fractures, thus presenting high specificity.
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MRI is more sensitive than CT and BS in the detection of bone metastasis, because it detects small metastases in the bone marrow (where metastases begin) before the remodeling has occurred. 39 On MRI, bone metastases show a low T1 signal, a high T2/short tau inversion recovery signal and enhance. Conventional MRI lacks whole-body coverage, but it is possible to cover the whole spine and pelvis (in which the majority of PCa metastases occur) in a short time. Other indications for MRI are the evaluation of epidural metastatic involvement that compresses the spinal cord and the evaluation of equivocal findings with other techniques. 40 Newer MRI techniques, such as wbMRI, for evaluating the entire skeleton have recently been evaluated. This is a recent development (an "all-in-one" tumor-node-metastasis assessment) using large field-of-view coronal images of the chest, abdomen, pelvis and bone: it is carried out in <1 h with no irradiation, and the sensitivity for small bone metastases is approximately 100%. 41 However, this technique is not widely available, as it is expensive and time-consuming. Furthermore, even if wbMRI might be considered the highest accurate technique for bone evaluation, the assessment of the nodal involvement remains low. Finally, in recent years, novel fusion imaging techniques, such as combined PET/ MRI, have shown a high potential impact for PCa staging, but it is not yet widely available due to the high costs. 39 Staging of PCa with molecular imaging PET/CT radiopharmaceuticals for imaging PCa 18F-FDG: 18F-FDG is not currently used in clinical practice for PCa, and it will probably remain marginal in the future in PCa because of its low glycolytic activity. However, it could have a limited clinical application in centers without access to alternative tracers and in patients with Gleason scores 9 or 10 or in castration-resistant PCa.
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Choline: Choline is a precursor of phosphatidylcholine, the most diffused membrane phospholipid in human cells. Increased uptake of this tracer has been shown in several cancers including PCa. Choline can be labeled with either C-11 or F-18. In the latter case, it is possible for commercial distribution in centers with no onsite cyclotrone (Fig. 4) . In the past decade, choline has been extensively used in PCa worldwide, either for staging or restaging the disease in the case of BR.
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18F-FACBC: 18F-FACBC is an L-leucine analog that has recently been applied in PCa imaging. 44 Preliminary data were published in staging and BR where it showed a small superiority over choline. 45 However, the advantages of using this tracer on a large scale is yet to be fully shown, and the contemporaneous development of other tracers might limit its use in the future.
PSMA: PSMA is a glutamate carboxypeptidase II, and is a relatively new tracer for the imaging of PCa and for several other tumors. 46 Ga is the most common isotope labeled to PSMA; it allows even small centers not equipped with a cyclotron to obtain and use the tracer. Currently, the most used radiopharmaceutical is Ga-PSMA-HBED developed in Heidelberg. 47 In addition to Ga-based tracers, a few promising fluorinated compounds (e.g. 18F-PSMA 1007 48 ) have been developed, and due to favorable characteristics and easy access, might soon be available in more centers around the world. The emerging role of this tracer in the world of molecular imaging is evidenced by recently published joint guidelines between the European Association of Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging. 48 Clinical studies for preoperative staging of PCa with molecular imaging For the purpose of local staging, many studies have investigated different PET/CT tracers with controversial results. A recent publication reported that Ga-PSMA correctly identified PCa within the prostate in >90% of high-risk PCa patients scheduled for surgery. However, in this application, MRI is the imaging of choice, as it can show the anatomy of cancer with higher precision. A combination of PSMA PET and MRI (PET/MRI) could increase sensitivity and specificity in the future, but costs are the main limitations. 49 Regarding nodal staging, a meta-analysis showed a sensitivity of choline PET/CT of 49.2% and a specificity of 95%. In the same patient population, CT and MRI had a sensitivity and a specificity of 42 and 82%, and 39 and 82%, respectively. In this population, the added usefulness of choline PET/CT was its high PPV. 50 Ga-PSMA has recently been investigated for staging PCa with promising high sensitivity.
In a recent study enrolling 130 patients with intermediateand high-risk PCa, who underwent RP with LN dissection, the sensitivity and specificity of Ga-PSMA PET for the detection of nodal metastasis using histopathology as the gold standard were 65.9% and 98.9%, respectively. 50 In an Australian study, 30 patients with intermediate-or high-risk PCa were studied with Ga-PSMA before surgery: in this population 11 of 30 patients showed LN metastases after surgery. On a patient basis, 68 Ga-PSMA PET/CT had a sensitivity of 64% and a specificity of 95%, a PPV of 88%, and a NPV of 82%. On a region-based analysis, the sensitivity of 68 Ga-PSMA PET/CT was 56%, the specificity was 98%, the PPV was 90% and the NPV was 94%. It is interesting to point out that the mean size of missed LN metastasis at 68 Ga-PSMA PET/CT was 2.7 mm. 51 In another very recent study, 12 high-risk PCa patients who underwent 68 Ga-PSMA PET/CT for staging before RP along with extended LN dissection were included in the analysis. 68 Ga-PSMA PET/CT and MRI were compared with final histopathology for detection of metastatic LNs. Sensitivity, specificity, PPV, NPV and accuracy were 66 Cu-PSMA PET/CT was positive in seven of eight patients, with a sensitivity of 87.5%, specificity of 100%, PPV of 100% and NPV of 93.7%. 53 The main limitation of PET/CT for nodal assessment is its limited spatial resolutions (approximately 5 mm), which hinders the identification of most of the initial nodal deposits. For preoperative staging, PET/CT has shown small superiority in terms of sensitivity (approximate 10% of increase in sensitivity) with respect to conventional imaging: for this reason and also due to costs and availability, PET/CT has not yet gained a prominent position as upfront staging of PCa.
To date, taking all these considerations into accounts, pelvic LN dissection is still the gold standard in the evaluation of nodal stage in selected patients with PCa. 5 
Current clinical practice guidelines and controversies regarding preoperative staging
The recommendation for preoperative staging of PCa patients varies between the different clinical practice guidelines. We will take into consideration the main published guidelines that arise from the EAU, 5 the AUA, 54 the NCCN, 55 the NICE 56 and the ACR. 15 TRUS is mostly carried out with the aim of localizing the prostate gland during systemic biopsy. The EAU guideline suggest that TRUS and its derived techniques, such as 3-D and color Doppler TRUS, have no sufficient accuracy to be recommended for routine staging in PCa. 5 To date, MRI is regarded as the most sensitive and specific imaging technique for PCa detection and staging, and it is routinely recommended for local staging by most of the guidelines. 6 In the near future, some limitations should be resolved: indeed, high-quality prostate MRI is not always available in all centers, and MRI is still an expensive and time-consuming test.
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The last published EAU, NCCN and ACR guidelines mention the essential role of MRI staging of the primary lesion.
As discussed above, MRI has low sensitivity for focal microscopic extraprostatic extension, but provides an accurate anatomical view of the tumor location. Thus, even if the EAU guideline discourages the routine use for local staging among low-risk patients, the EAU, ACR and NCCN guidelines recommend MRI in all intermediate-or high-risk patients in order to plan the surgical management. 5, 15, 56 The use of cross-sectional imaging techniques has very low sensitivity (<40%) for nodal staging of PCa. The EAU, AUA and ACR guidelines recommend using cross-sectional imaging techniques to assess the N stage in intermediate-and high-risk patients, 5, 15, 54 and the NCCN and NICE guidelines recommend CT or MRI as part of the staging work-up only in high-risk patients. 55, 56 The role of PET/CT in PCa staging is rapidly increasing, and several new radiotracers have been introduced with promising results. 7 However, to date, PET/ CT is not routinely recommended, mainly because of the high costs and only a small superiority compared with the standard methods. 59, 60 The EAU guideline is the only guideline that mentions the potential role of choline PET/CT in LN staging, discouraging routine use because of its inadequate sensitivity. 5 Another important controversy in the current guidelines is represented by M staging. The conventional method suggested for evaluating bone metastasis of PCa is represented by BS, but the performance of this imaging depends greatly on the tumor's features, such as PSA value, clinical stage and the Gleason score. 5 At this time, all the guidelines still recommend the use of BS in selected (intermediate-and high-risk PCa) or symptomatic patients, even if BS still has a very low DR. Increasing evidence has shown that wbMRI and PET/CT are more accurate than BS, and they will probably have an important role in the future (Table 1) . 61 
Re-staging after primary treatment
PCa relapse is usually suspected because of BR that is defined by two consecutive increases of PSA >0.2 ng/mL after RP or an increase of >2 ng/mL from the initial PSA nadir value after RT. 5 Recurrence might be local (in the prostatic bed), distant (presence of metastases) or a combination of both. After detecting BR, imaging could help clinicians to assess the location and the extent of the recurrence, and to plan the disease management.
Conventional imaging, such as CT and BS, are often useless, whereas MRI and PET/CT are becoming the mainstay tools for re-staging. This is mainly due to the higher accuracy and the likelihood of earlier detection of the site of the relapse.
mpMRI for local re-staging (pelvic MRI) and bone metastasis detection (wbMRI)
MRI is nowadays one of the most accurate examinations to evaluate recurrent PCa after primary treatment.
62-65 MRI can be useful to identify small local cancer recurrence in a range of PSA-relapse between 0.2 and 1 ng/mL. 66 The MRI protocol should include morphological T2WI with high spatial resolution technique (3-4 mm), DCEI and DWI with an ADC map. Magnetic resonance spectroscopy might be helpful, but it is not routinely used. 15 Recurrent PCa after RP can be recognized as any soft tissue mass in the surgical bed with slightly higher T2 SI than the adjacent muscle, restricted diffusion, and rapid wash-in and wash-out at DCE. Several studies have shown the utility of MRI for the detection of local recurrence after RP (Fig. 5) with a specificity and accuracy close to 90%; however, the average PSA level in these studies was >0.5 ng/mL, which represents the current threshold for salvage therapy. 67, 68 To date, only a few studies have evaluated the role of MRI identifying early recurrence after RP with a PSA level <0.5 ng/mL, with promising results showing a sensitivity of 86%. 69 Relapse after RT is commonly located close to the native tumor. RT causes significant changes in the prostate, such as atrophy and fibrosis of the gland, fatty replacement, increased bladder or rectal wall thickness, thickening of perirectal fascia, and increased SI of pelvic musculature. 70 DCE is the pivotal sequence to find any trace of recurrence, because the neoplastic tissue is characterized by early enhancement, whereas irradiated tissue presents low or late enhancement (Fig. 6) . Furthermore, T2WI may be confusing because both recurrence and surrounding tissue could present low T2 SI. 15 Even in this field, MRI has shown excellent results with a sensitivity of 95% and specificity of 89%; 71, 72 furthermore, MRI could guide biopsy for an eventual further salvage treatment. Table 3 summarizes all patterns of SI of PCa recurrence and other pelvic tissues, such as fibrotic tissue or residual gland.
Bone, after LNs, is the second most common site of metastases for PCa. 73 wbMRI has been recently introduced as a diagnostic tool for bone metastases detection showing promising results, with a pooled sensitivity and specificity of 95% and 92%, respectively. wbMRI has proved to be comparable with 18F-FDG PET/CT for bone disease detection. 75, 76 The DWI sequence raises the pooled sensitivity and specificity of the technique to 95% and 92% on a per-patient analysis, and to 91% and 94% on a per-lesion analysis, respectively. 77 In contrast, DWI alone is not reliable because of high false positive rates and it needs to be correlated with morphological sequences. 74 The altered trabecular bone density, neo-angiogenesis, alterations of bone marrow fat, water or iron content are all targets for MRI. Tumor cell density can be evaluated on morphological T1/T2WI and DWI. In addition, gradient-echo imaging sequences can detect displacement of normal bone marrow fat by tumor cells and matrix mineralization, thanks to the ability to discriminate bone marrow water and fat with Dixon MRI. 78, 79 The response of metastases to treatment can be assessed within 1-3 months after the start of therapy. However, considering that metastases might behave differently in the same patient, it can be difficult to understand the conclusive effectiveness of treatment. For these reasons, histogram analyses can help to assess the global patient response. 78 As reported by Padhani et al., several patterns of therapy response can be recognized, on a lesion-by-lesion assessment, by evaluating the SI and ADC. In general, an increase of ADC values, not due to the "T2 shine through" effect and confirmed in morphological sequences is considered as a positive response.
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Re-staging after primary treatment with BS and PET/CT BS is the traditional imaging method to detect PCa bone metastases. It takes advantage of the ability of metastases to induce a strong osteoblastic reaction, which is able to accumulate the tracer by producing an increased calcium deposit. 82 BS, however, proves to have a relatively low sensitivity in a per-lesion analysis because it cannot detect early lesions (which are osteolytic for a short period) and is planar (bone single-photon emission computed tomography is usually carried out only on positive findings).
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Nowadays, BS is used in the diagnostic flow chart of PCa patients in many different clinical settings. Thanks to new semiquantitative software, it is also possible to standardize and measure the BS index, which is an imaging biomarker of the extent of whole-body bone metastasis. This index allows a more accurate therapy assessment than visual interpretation only. Furthermore, it is strongly correlated with life expectancy, representing a good indicator of prognosis. 84 11 C-choline or 18 F-choline PET/CT has mostly been investigated in restaging after primary treatment. 85 However, its diagnostic accuracy is still suboptimal. 86 Reported data show a variable DR according to PSA level, ranging from 36% if PSA relapse is <1 ng/mL to 73% if PSA at relapse is >3 ng/mL. 87 Interesting performances and higher clinical impact were found in those patients with low trigger PSA and a fast PSA kinetic, expression of a more aggressive disease. In these cases, an early and focused treatment can modify the patient's prognosis. 88, 89 These results have been used to drive the most appropriate therapeutic approach, and were proved to have a significant impact in radiotherapy plan drawing and the salvage surgical approach, such as salvage LN dissection or systemic therapy. 90, 91 Finally, it seems that a positive 11 C-choline PET/CT finding during restaging could predict PCa-specific survival if carried out during BR, both in hormone-na€ ıve patients and in patients already treated with androgen deprivation therapy. These data show that 11 C-choline PET/CT should be more widely used in the follow up of PCa patients receiving metastasis-directed therapies. 92, 93 FACBC has been extensively studied in patients with recurrent PCa. In preliminary studies, FACBC was shown to be clearly superior to 111 In-capromab pendetide in patients with BR. 94, 95 In a large pooled population of patients with BR, an overall positivity rate of 67.7% for FACBC was reported. However, the DR in the lowest serum PSA quartile (≤0.79 ng/ mL) was as low as 41.4%. 96 In a prospective comparison with 11 C-choline in 89 patients, 97 18 F-fluciclovine resulted in being slightly superior in terms of sensitivity and superior in terms of specificity. In particular, the 11 C-choline and 18 F-FACBC, sensitivities were 32% and 37%, the specificities 40% and 67%, the accuracies 32% and 38%, the PPVs 90% and 97%, and the NPVs 3% and 4%, respectively. 88, 98 To date, 68 Ga-PSMA is considered the best available imaging modality for the precise detection of the site of recurrence, especially in early BR (Fig. 7) .
The oncoming widespread use of 68 Ga-PSMA is mainly due to choline PET/CT limitations, such as the low sensitivity in the case of low PSA values, 99 when a salvage therapy is more effective because the cancer burden is still limited. 100 In a population of 248 recurrent PCa patients (median PSA 1.99 ng/mL), the authors reported a positivity rate of 89.5% in the whole population. In other subgroups, they reported a DR of 93.0% for PSA values between 1 and 2 ng/mL, 72.7% for PSA values between 0.5 and 1 ng/mL, and 57.9% for PSA values between 0.2 and 0.5 ng/mL. Other authors substantially confirmed the same results, which represents the base for an increasing application of PSMA in the clinical routine. 9, [99] [100] [101] [102] It is important, however, to point out that 68 Ga-PSMA has a lower sensitivity for local relapse detection because of its urinary excretion, and is therefore significantly accumulated in the urinary bladder. Furthermore, the occasional uptake in nervous ganglia might reduce the specificity in some cases.
Current clinical practice guidelines and controversies regarding secondary staging for biochemical recurrence after primary treatment Approximately 30% of patients undergoing PR and RT will develop a BR. 103, 104 Conventional imaging techniques, such as CT and BS, are often useless in cases of PSA <10 ng/mL, low PSA kinetics or in asymptomatic patients. However, in newly diagnosed polymetastatic disease, conventional imaging techniques might be useful.
Currently, new imaging techniques, such as MRI and PET/ CT, are increasingly used, allowing clinicians the early detection of PCa recurrence. However, to date, there is poor consensus among urological associations' guidelines about which diagnostic tests should be carried out in the presence of BR. However, an extensive imaging work-up should be addressed only when a clear modification of the clinical management is expected.
Herein, we report the recommendation of the EAU, 5 AUA, 54 NCCN 55 and NICE 56 guidelines about secondary staging for BR after primary treatment.
The EAU discourage the use of imaging when the PSA level is <1 ng/mL. 5 Carrying out conventional imaging, such as CT and BS, in secondary staging depends greatly on PSA value and PSA kinetics. Therefore, the EAU guidelines suggest to carry out BS and/or abdominopelvic CT only in patients with PSA >10 ng/mL, or with adverse PSA kinetics (PSA doubling time <6 months, PSA velocity >0.5 ng/mL/ month). 5 The EAU guidelines recommend PET/CT for secondary staging after RP and RT, 5 and recommend using choline or 68 Ga-PSMA for the detection of bone or LN metastasis in men with BR after RP who have PSA levels >1 ng/mL. 5 The EAU has also dedicated a section on the role of wband axial-MRI, concluding that, at this time, the role of these techniques in detecting occult bone or LN metastases in the case of BR remains to be clarified. 5 Regarding secondary staging after RT, the ideal PSA cutoff for choline PET/CT is still unclear. 5 Furthermore, no robust evidence is currently available in the literature about 68 Ga-PSMA PET/CT in patients with BR after RT. 5 Therefore, the EAU guidelines recommend choline PET/CT to rule out LNs or distant metastases in patients suitable for curative salvage treatment after RT. 5 The greatest benefits of salvage RT in patients who developed BR after RP occurs when the PSA level is ≤0.5 ng/mL. 5 At this PSA level, even if CT and BS are useless, the role of MRI and PET/CT with choline and 68 Ga-PSMA might be limited, 5 and most patients at risk of local relapse should undergo salvage RT without local imaging. 5 Regarding BR after RT, the EAU guidelines suggest that both MRI and PET/CT can be used for the assessment of local recurrence. 5 However, because of the potential morbidity of salvage options, only patients suitable for further treatments should undergo these imaging techniques. 5 Furthermore, histological proof of local recurrence is mandatory before any salvage treatment. 5 Thus, EAU guidelines suggest carrying out MRI only in patients who are considered candidates for local salvage therapy, even with the aim to detect abnormal areas and guide biopsies. 5 The AUA guidelines suggest that improved imaging techniques would help to better define appropriate therapies, although the exact type of imaging is not specified. 54 The NCCN guidelines recommend secondary staging after RT only in patients who are candidates for local therapy. They suggest that the work-up typically includes BS and prostate MRI; however, abdominopelvic CT/MRI and 11 C-choline PET can be considered as part of staging imaging. 55 The NICE guidelines suggest that MRI should not be routinely carried out in patients with BR after primary treatment, although they recommend BS in symptomatic patients or when the trend PSA relapse is suggestive of metastatic spread.
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Conclusions
The traditional imaging techniques in the staging and re-staging of PCa are still limited. Newer imaging techniques, such as mp-and wbMRI and PET/CT, particularly when carried out with the most recent radiotracers, have the potential to fill the historical lack of conventional imaging methods both in primary and secondary staging of PCa.
The role of MRI is increasing in PCa, and is becoming a crucial tool in all clinical situations, not only for diagnosis and staging, but also for treatment planning; MRI can also detect local recurrence with a high sensitivity, and is considered the most accurate imaging tool in the identification of small bone metastases and in the assessment of therapeutic response. Also, PSMA PET/CT is becoming an important tool for PCA management: according to recent literature, PSMA might have a higher sensitivity than conventional imaging for preoperative staging of high-risk patients, but is still not cost-effective and many limitations remain in the staging setting of PCa patients. Furthermore, PSMA PET/ CT is the best imaging modality in early BR and might become a standard tool for the early diagnosis of PCa recurrence.
